pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX
Edgewise Therapeutics
Edgewise Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1715 38th St., Boulder, CO 80301, US
- Founded
- 2017
- Employees
- 154
- Programs
- 15
- Drugs
- 3
- Patents
- 7
Edgewise Therapeutics patents
7 pharmaceutical patents indexed for Edgewise Therapeutics. 0 expire within 24 months.
Edgewise Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12415794
Pyridazinone compounds and uses thereof
granted -
US 12240831
Pyridazinone compounds and uses thereof
granted -
US 12240833
Pyridazinone compounds and uses thereof
granted -
US 12012395
Pyridazinone compounds and uses thereof
granted -
US 11390606
Pyridazinone compounds and uses thereof
granted -
US 11236065
Pyridazinone compounds and uses thereof
granted -
US 11091464
Pyridazinone compounds and uses thereof
granted
Frequently asked questions
How many patents does Edgewise Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Edgewise Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.